First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruiting · NCT04067336 · Registry updated 2026-05-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT04067336 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kura Oncology, Inc. | 11 |
43 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.